Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
October 14, 2003
Assignee:
Genentech, Inc.
Inventors:
Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
September 16, 2003
Assignee:
Genentech, Inc.
Inventors:
Ross G. Clark, Henry B. Lowman, Iain C.A.F. Robinson
Abstract: A method is disclosed for separating a polypeptide monomer from a mixture comprising dimers and/or multimers. The method comprises applying the mixture to either a cation-exchange chromatography resin or an anion-exchange chromatography resin and eluting the mixture at a gradient of about 0-1 M of an elution salt, wherein the monomer is separated from the dimers and/or multimers present in the mixture.
Abstract: A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.
Type:
Grant
Filed:
November 27, 2000
Date of Patent:
August 26, 2003
Assignee:
Genentech, Inc.
Inventors:
Dana C. Andersen, Tiffany M. Bridges, Martin Gawlitzek, Cynthia A. Hoy
Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
August 19, 2003
Assignee:
Genentech, Inc.
Inventors:
Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
Abstract: A process is described for monitoring the effectiveness of a purification process in removing plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof. This process comprises incubating the sample with a protease capable of specifically cleaving the Arg275—Ile276 bond of human wild-type tPA and then with denaturing/reducing agents in respective amounts effective to reduce the disulfide bonds of human wild-type tPA; subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile from the chromatography step for the amount of PA endogenous to the CHO cells present therein.
Abstract: A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
Type:
Grant
Filed:
March 30, 2000
Date of Patent:
May 6, 2003
Assignee:
Genentech, Inc.
Inventors:
James Q. Oeswein, John R. Smikahl, Sharon X. Wang, Douglas A. Yeung
Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
Abstract: IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
Abstract: A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding said glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.
Type:
Grant
Filed:
April 21, 2000
Date of Patent:
January 14, 2003
Assignee:
Genentech, Inc.
Inventors:
Dana C. Andersen, Tiffany M. Bridges, Martin Gawlitzek, Cynthia A. Hoy
Abstract: An isolated TGF-&bgr; supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-&bgr; supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-&bgr; supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.
Type:
Grant
Filed:
September 21, 1993
Date of Patent:
September 24, 2002
Assignee:
Genentech, Inc.
Inventors:
Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
Type:
Grant
Filed:
June 22, 1999
Date of Patent:
July 16, 2002
Assignees:
Genetech, Inc.
Inventors:
Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicholas J. Skelton
Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16,25,49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
Type:
Grant
Filed:
January 5, 2000
Date of Patent:
June 11, 2002
Assignee:
Genentech, Inc.
Inventors:
Yves Dubaquie, Paul J. Fielder, Henry B. Lowman
Abstract: Human insulin-like growth factors is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factors.
Abstract: Human insulin-like growth factor is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factor.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 18, 2001
Assignee:
Genentech, Inc.
Inventors:
James M. Lee, Axel Ullrich, Arjun Singh
Abstract: A process is described for purifying plasmid DNA from prokaryotic cells comprised thereof. This process comprises the steps of: (a) digesting the cells; (b) incubating the cells for about 4 to 24 hours to effect lysis and solubilization thereof, without effecting enzymatic digestion of RNA; (c) removing lysate contaminants from the cells to provide a plasmid DNA solution; (d) filtering the solution through a tangential flow filtration device to obtain a retentate containing the plasmid DNA; and (e) collecting the retentate.
Type:
Grant
Filed:
July 21, 2000
Date of Patent:
November 6, 2001
Assignee:
Genentech, Inc.
Inventors:
Michelle D. Butler, Darien L. Cohen, David Kahn, Marjorie E. Winkler
Abstract: A process for purifying molecules from contaminants is provided. In this process a mixture containing the molecule (peptide, polypeptide, or biologically active non-peptidyl compound) and its contaminants is loaded onto a reversed-phase liquid chromatography column and the molecule is eluted from the column with a buffer containing hexylene glycol.
Abstract: Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid encoding a protein that displays DNA-digesting activity, wherein these nucleic acids are linked to a first promoter, and nucleic acid encoding the heterologous polypeptide, which nucleic acid is linked to a second promoter, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate.
Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Type:
Grant
Filed:
March 31, 1998
Date of Patent:
June 26, 2001
Assignee:
Genentech, Inc.
Inventors:
Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
Abstract: Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid encoding a protein that displays DNA-digesting activity, wherein these nucleic acids are linked to a first promoter, and nucleic acid encoding the heterologous polypeptide, which nucleic acid is linked to a second promoter, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate.